Heartland Advisors Inc. Reduces Holdings in Smith & Nephew SNATS, Inc. $SNN

Heartland Advisors Inc. decreased its position in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) by 27.2% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 300,567 shares of the medical equipment provider’s stock after selling 112,426 shares during the quarter. Heartland Advisors Inc.’s holdings in Smith & Nephew SNATS were worth $9,862,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Garner Asset Management Corp purchased a new position in shares of Smith & Nephew SNATS during the fourth quarter worth about $27,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Smith & Nephew SNATS during the third quarter worth about $41,000. Northwestern Mutual Wealth Management Co. grew its holdings in shares of Smith & Nephew SNATS by 105.8% during the third quarter. Northwestern Mutual Wealth Management Co. now owns 1,385 shares of the medical equipment provider’s stock worth $50,000 after purchasing an additional 712 shares during the last quarter. Huntington National Bank grew its holdings in shares of Smith & Nephew SNATS by 1,837.0% during the third quarter. Huntington National Bank now owns 1,414 shares of the medical equipment provider’s stock worth $51,000 after purchasing an additional 1,341 shares during the last quarter. Finally, Farther Finance Advisors LLC grew its holdings in shares of Smith & Nephew SNATS by 81.9% during the fourth quarter. Farther Finance Advisors LLC now owns 1,697 shares of the medical equipment provider’s stock worth $56,000 after purchasing an additional 764 shares during the last quarter. Hedge funds and other institutional investors own 25.64% of the company’s stock.

Smith & Nephew SNATS Stock Performance

Shares of NYSE:SNN opened at $30.96 on Thursday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.25 and a current ratio of 2.57. Smith & Nephew SNATS, Inc. has a 52 week low of $28.40 and a 52 week high of $38.79. The company has a 50-day moving average price of $31.35 and a 200 day moving average price of $32.86.

Smith & Nephew SNATS (NYSE:SNN) last announced its quarterly earnings data on Tuesday, February 17th. The medical equipment provider reported $29.55 EPS for the quarter. The firm had revenue of $1.60 billion during the quarter. As a group, research analysts predict that Smith & Nephew SNATS, Inc. will post 2.25 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have issued reports on SNN shares. Wall Street Zen lowered Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Sanford C. Bernstein set a $31.85 target price on shares of Smith & Nephew SNATS in a research note on Monday, May 11th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research note on Monday, April 20th. Kepler Capital Markets downgraded shares of Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a research note on Thursday, June 4th. Finally, The Goldman Sachs Group reiterated a “buy” rating on shares of Smith & Nephew SNATS in a research note on Monday, May 25th. One investment analyst has rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $30.93.

Smith & Nephew SNATS Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.